Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias

QJM: An International Journal of Medicine

Volumn 92, Issue 7, 1999, Pages 387-394

  Wierzbicki, A S ^a   Lumb, P J ^a   Semra, Y ^a   Chik, G ^a   Christ, E R ^a   Crook, M A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERLIPEMIA; FEMALE; HEADACHE; HUMAN; IMPOTENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0032769877     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.7.387     Document Type: Article

References (19)

1. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Jacotot B, Mathe D, Frucharty J-C, eds. Atherosclerosis X. Amsterdam, Elsevier, 1995:307-10.
2. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Braces P, Black DM. A multicentre, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolaemia. Am J Cardiol 1997; 80:39-44.
3. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D, for the atorvastatin study group. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia. Am J Cardiol 1997; 79:1475-81.
4. Jones PJ, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin patients with hypercholesterolaemia (the CURVES study). Am J Cardiol 1998; 81:582-7.
5. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High-dose atorvastatin therapy compared with traditional therapeutic regimes in severe heterozygous familial hypercholesterolaemia. Q J Med 1998; 91:291-4.
6. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Experience with simvastatin-fenofibrate combination therapy compared to simvastatin-cholestyramine therapy for familial hypercholesterolaemia. Q J Med 1997; 90:631-4.
7. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thromb Vasc Biol 1995; 15:678-82.
8. Bakker-Arkema R, Davidson MH, Goldstein RJ, Davignon J, Isaacson JL, Weiss SR, Keilson LM, Brown V, Miller T, Shurinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridaemia. JAMA 1996; 275:128-33.
9. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridaemia. Am J Cardiol 1998; 81:66-9B.
10. Foster LF, Stewart G, Bedford DK, Stewart JP, Caslake MJ, Packard CJ, Shepherd J, Black DM. Stable isotope turnover studies of apolipoprotein B in combined hyperlipidaemia before and after treatment with atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thromb Vasc Biol 1996; 11 (supplement):41, abstract 06356.
11. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins. JAMA 1998; 279:1643-50.
12. Saloma V, Rasi V, Pekannen J, Vahtera E, Jauhianen M, et al. Haemostatic risk factors and prevalent coronary heart disease: the FINRISK haemostasis study. Eur Heart J 1994; 15:1293-9.
13. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective agent in familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 1997; 17:1527-32.
14. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effects of atorvastatin on plasma fibrinogen. Lancet 1998; 351:591-2.
15. Jerling JC, Vorster HH, Oosthuizen W, Vermakk WJH. Effects of simvastatin, a 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor, on the haemostatic balance of familial hypercholesterolaemic subjects. Fibrinolysis Proteolysis 1997; 11:91-6.
16. Nair DR, Papdakis JA, Jagroop IA, Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet 1998; 351:1430.
17. Wierzbicki AS, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351:1430-1.
18. Black DM, Bakker-Arkema RC, Nawrocki JW. An overview of the clinical safely profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Ann Intern Med 1998; 158:577-84.
19. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA. The efficacy and safety and six week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79:38-42.